Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020
— Robust efficacy with evidence of a dose response —— 6/6 patients rescue-injection-free in cohort 1, with 3 patients at […]
